BillionToOne Q2 FY26 net income turns to USD 8.1 million; revenue rises 64% to USD 109.4 million
BLLN•Guidance and product launch plans
BillionToOne reiterated 2026 revenue guidance of $450 million-$465 million; plans the Unity Fetal Risk Screen 130-gene panel launch on Aug. 17, 2026.
Q2 revenue and profit rise sharply
BillionToOne posted Q2 2026 revenue of $109.4 million, up 64% year over year.
Operating income was $5.5 million, swinging from an operating loss a year earlier; net income was $8.1 million, or $0.15 per diluted share.
Gross margin widened 5 percentage points to 70%; tests delivered rose 35% to 196,000.
Prenatal and oncology testing growth
Prenatal testing revenue rose 55% to $94.2 million; oncology testing revenue more than doubled to $13.7 million.
